Summary
56 / 100 · Bulios Score
What speaks for it
- Revenue grew by 10.0% a year over the last 3 years.
- It could repay all its net debt from 0.4 years of operating profit.
What to watch
- It cut its dividend by 17% last year.
- The share price is above the Bulios Fair Price.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 15.7 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 8.7% a year over 5 years. Over the last 3 years it grew by 10.0% a year. For the next fiscal year analysts expect revenue to grow by 8.2%.
Growth in detailDoes it make money?
PoorlyWhere 100 JPY of revenue goes
- Cost of sales 79 JPY
- Sales and administration 17 JPY
- Taxes and other 1.0 JPY
- Net profit 2.9 JPY
Net profit, industry median (Medical - Pharmaceuticals) 4.8 JPY
Out of every 100 JPY of revenue, 2.9 JPY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 1.22%
- Paid out of profit
- 19%
You receive $0.49 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 1
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.